Skip to main content

Table 2 Overview of the R-LiNK work packages

From: Prospective cohort study of early biosignatures of response to lithium in bipolar-I-disorders: overview of the H2020-funded R-LiNK initiative

Work package Aims
1 Project administration
2 Set-up, ethical approval, database development
3 Identification of baseline & follow-up assessment of clinical symptoms, neuropsychological and social functioning, illness activity, etc
Characterisation of the clinical response phenotype for lithium treatment according to pre-defined outcome measures (categorical/continuous)
Assessment & optimization of medication adherence
Economic modelling of using a stratified approach to prescribing lithium; Qualitative & quantitative assessment of the digital phenotype
Development of a prototype device for salivary lithium measurement
4 Examination of neuro-imaging (MRI and 1H-spectroscopy) signature before & after lithium initiation to allow repeated assessment of e.g. architecture of the amygdala, etc
5 Assessment of 7Li-MRI signature (i.e. distribution of lithium in the brain measured 12 weeks after initiation of treatment)
6 Blood sampling to measure omics (e.g. putative transcriptomic, mirnomic, methylomic and proteomic biomarkers) before & after lithium initiation to explore potential molecular signatures
7 Data management infrastructure for e.g. data collection of heterogeneous data (imaging, genetics, clinical) across different institutions & countries; Quality control of data processing; controlled data sharing; etc
Data analysis
8 Evaluation of laboratory to bedside transferability of study findings according to e.g. clinical feasibility, technical feasibility, utility of markers when employed alone or in combination (i.e. additivity or redundancy), acceptability & cost effectiveness
9 Communication & dissemination of findings